Bepridil (hydrochloride hydrate)

Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca+ channel antagonist and Na+, K+ channel inhibitor, with antianginal and type I antiarrhythmic effects. Bepridil hydrochloride hydrate also acts as a cardiac Na+/Ca2+ exchange (NCX1) inhibitor. Bepridil hydrochloride hydrate can be used for the research of cardiovascular disorders[1][2][3][4][5].

[1]A Gill, et al. Pharmacology of Bepridil. Am J Cardiol. 1992 Apr 9;69(11):11D-16D.|[2]D R Harder, et al. Bepridil Blockade of Ca2+-dependent Action Potentials in Vascular Smooth Muscle of Dog Coronary Artery. J Cardiovasc Pharmacol. Jul-Aug 1981;3(4):906-14.|[3]Yasuhide Watanabe. Cardiac Na +/Ca 2+ Exchange Stimulators Among Cardioprotective Drugs. J Physiol Sci. 2019 Nov;69(6):837-849.|[4]A Yatani, et al. Bepridil Block of Cardiac Calcium and Sodium Channels. J Pharmacol Exp Ther. 1986 Apr;237(1):9-17.|[5]J C Wang, et al. Bepridil Differentially Inhibits Two Delayed Rectifier K(+) Currents, I(Kr) and I(Ks), in Guinea-Pig Ventricular Myocytes. Br J Pharmacol. 1999 Dec;128(8):1733-8.|[6]L Z Benet, et al. Pharmacokinetics and Metabolism of Bepridil. Am J Cardiol. 1985 Mar 15;55(7):8C-13C.Università Vita-Salute San Raffaele. 2022 Apr 08. 34.|Eur J Pharm Sci. 2021, 105889.|Eur J Pharm Sci. 2023 May 22;106475.|Research Square Preprint. 2024 Feb 9.|Virology. 2020 Jan 2;539:38-48.